AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24767603 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity online CBT-based treatment consisting of six weekly modules; participants receive weekly post-session feedback.
Number of subjects: 0
Study 24767603 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group; participants do not receive the intervention during the waiting period.
Number of subjects: 0
Study 22864500 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes care quality improvement initiative adapted for FQHCs
Number of subjects: 0
Study 20339354 — intervention group
Group type: EXPERIMENTAL
Intervention: Hourly mean method
Number of subjects: 422
Study 18823460 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative i.v. fluid loading with a balanced crystalloid solution (1 ml/kg/h over 48 h)
Number of subjects: 44
Study 18823460 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pre-operative fluid loading)
Number of subjects: 44
Study 15912340 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing aids
Number of subjects: 15
Study 15912340 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hearing aids)
Number of subjects: 15
Study 12043481 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 0
Study 12043481 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (SSRI)
Number of subjects: 0
Study 12043481 — intervention group
Group type: COMPARATOR
Intervention: Preventive intervention programmes
Number of subjects: 0
Study 12043481 — intervention group
Group type: COMPARATOR
Intervention: Clinic-based interventions for suicidal adolescents
Number of subjects: 0
Study 10614059 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet high in saturated fat
Number of subjects: 0
Study 10614059 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet high in polyunsaturated fat
Number of subjects: 0
Study 7595953 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse palpation (touch)
Number of subjects: 60
Study 7595953 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cold pressor/pulse palpation
Number of subjects: 60
Study 7595953 — intervention group
Group type: COMPARATOR
Intervention: Cold pressor test (stressor)
Number of subjects: 60
Study 7595953 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 60
Study 2234818 — intervention group
Group type: EXPERIMENTAL
Intervention: Panretinal photocoagulation (PRP) in group A
Number of subjects: 53
Study 2234818 — intervention group
Group type: EXPERIMENTAL
Intervention: Panretinal photocoagulation (PRP) in group B
Number of subjects: 53
Study 2234818 — intervention group
Group type: COMPARATOR
Intervention: Comparison between group B and A after PRP
Number of subjects: 53
Study 2234818 — intervention group
Group type: COMPARATOR
Intervention: Regression of neovascularization and visual acuity
Number of subjects: 53
Study 358845 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextro-amphetamine
Number of subjects: 13
Study 31625020 — intervention group
Group type: EXPERIMENTAL
Intervention: High expression of CD3, CD4, CD8, and CD45RO at the invasive margin (IM)
Number of subjects: 88
Study 31625020 — intervention group
Group type: EXPERIMENTAL
Intervention: High expression of CD4 and FOXP3 at the tumor center (TC)
Number of subjects: 88
Study 31625020 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined marker of CD3, CD8, CD45RO, and FOXP3
Number of subjects: 88
Study 31302291 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 18
Study 31302291 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 27256706 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose hUCB-MSCs (5.0 × 10^7)
Number of subjects: 34
Study 27256706 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose hUCB-MSCs (2.5 × 10^7)
Number of subjects: 34
Study 26357928 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 400
Study 26357928 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP(Flex)
Number of subjects: 400
Study 23179858 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide (Gb) 3.5 mg, intravenously or orally
Number of subjects: 8
Study 23179858 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolite M1 3.5 mg, intravenously
Number of subjects: 8
Study 23179858 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolite M2 3.5 mg, intravenously
Number of subjects: 8
Study 23179858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 21654053 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/d for six months
Number of subjects: 100
Study 21654053 — intervention group
Group type: COMPARATOR
Intervention: Control group (lower doses of statins)
Number of subjects: 100
Study 19505424 — intervention group
Group type: EXPERIMENTAL
Intervention: L-ornithine L-aspartate (LOLA) infusion (30 g daily for 3 days)
Number of subjects: 201
Study 19505424 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 201
Study 16861744 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginoscopic hysteroscopy (Group A)
Number of subjects: 300
Study 16861744 — intervention group
Group type: COMPARATOR
Intervention: Traditional hysteroscopy (Group B)
Number of subjects: 300
Study 16861744 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase I of the procedure (Group A)
Number of subjects: 300
Study 16861744 — intervention group
Group type: COMPARATOR
Intervention: Phase I of the procedure (Group B)
Number of subjects: 300
Study 16861744 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of hysteroscopy
Number of subjects: 300
Study 15531007 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 40 mg/d
Number of subjects: 1139
Study 15531007 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/d
Number of subjects: 1139
Study 15531007 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 80 mg/d
Number of subjects: 1139
Study 15531007 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 120 mg/d
Number of subjects: 1139
Study 15531007 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine 20 mg/d
Number of subjects: 1139
Study 15531007 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine 20 mg/d
Number of subjects: 1139
Study 15531007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1139
Study 15531007 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (any dose)
Number of subjects: 1139
Study 11531952 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART + IL-2
Number of subjects: 0
Study 11531952 — intervention group
Group type: COMPARATOR
Intervention: HAART alone
Number of subjects: 0
Study 9184112 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐(quinoxalin‐6 ylcarbonyl)piperidine (CX516)
Number of subjects: 0
Study 9184112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8486876 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ml 20% Lipofundin MCT/LCT (1/1) per day
Number of subjects: 20
Study 8486876 — intervention group
Group type: COMPARATOR
Intervention: 500 ml 20% Lipofundin S (LCT) infused over 8 h each evening
Number of subjects: 20
Study 3497041 — intervention group
Group type: EXPERIMENTAL
Intervention: Troleandomycin 2 g/day p.o. for 7 days
Number of subjects: 7
Study 3497041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 30074935 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose
Number of subjects: 100
Study 30074935 — intervention group
Group type: COMPARATOR
Intervention: Oral ferrous sulfate
Number of subjects: 100
Study 26952706 — intervention group
Group type: EXPERIMENTAL
Intervention: Both-bone intramedullary nailing
Number of subjects: 87
Study 26952706 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary nailing of ulna and plate fixation of radius
Number of subjects: 87
Study 26952706 — intervention group
Group type: COMPARATOR
Intervention: Both-bone plate fixation
Number of subjects: 87
Study 24531024 — intervention group
Group type: EXPERIMENTAL
Intervention: Superior LPI
Number of subjects: 208
Study 24531024 — intervention group
Group type: COMPARATOR
Intervention: Temporal LPI
Number of subjects: 208
Study 22108528 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week in-season resistance training program (EG)
Number of subjects: 25
Study 22108528 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 25
Study 19884374 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemonoxacin (TG-873870) 75 to 1,000 mg once daily for 10 days
Number of subjects: 46
Study 19884374 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemonoxacin (TG-873870) 500 mg cohort
Number of subjects: 46
Study 19884374 — intervention group
Group type: EXPERIMENTAL
Intervention: Nemonoxacin (TG-873870)
Number of subjects: 46
Study 19884374 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 18195171 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg consumption of 1 per day
Number of subjects: 21275
Study 18195171 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg consumption of >= 2 per day
Number of subjects: 21275
Study 18195171 — intervention group
Group type: COMPARATOR
Intervention: Egg consumption of < 1 per week
Number of subjects: 21275
Study 18195171 — intervention group
Group type: COMPARATOR
Intervention: Egg consumption of up to 6 times per week
Number of subjects: 21275
Study 18195171 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg consumption of >= 7 per week
Number of subjects: 21275
Study 18195171 — intervention group
Group type: EXPERIMENTAL
Intervention: HF without antecedent myocardial infarction
Number of subjects: 21275
Study 16870075 — intervention group
Group type: EXPERIMENTAL
Intervention: P‐ERMS (KADIAN) once‐daily (QD) dosing
Number of subjects: 112
Study 16870075 — intervention group
Group type: EXPERIMENTAL
Intervention: CRO (OxyContin) twice‐daily (BID) dosing
Number of subjects: 112
Study 12965981 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.95%‐tetrahydrocannabinol marijuana cigarette
Number of subjects: 67
Study 12965981 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5‐mg dronabinol (delta‐9‐tetrahydrocannabinol) capsule
Number of subjects: 67
Study 12965981 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 67
Study 11789210 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenmai injection (SM) with oxygen inhalation and anti-infection agents (SM 40 ml + 10% glucose 100 ml)
Number of subjects: 64
Study 11789210 — intervention group
Group type: COMPARATOR
Intervention: Aminophylline (AP) with 10% glucose (AP 0.25 g plus 10% glucose 100 ml)
Number of subjects: 64
Study 11789210 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (SM and AP)
Number of subjects: 64
Study 8874180 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cytarabine (HDAC) at 2 g/m2 intravenously every 12 hours for 12 doses plus daunorubicin (DNR) at 45 mg/m2/d intravenously for 3 days
Number of subjects: 665
Study 8874180 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose cytarabine (SDAC) 200 mg/m2/d for 7 days by continuous infusion plus daunorubicin (DNR) at 45 mg/m2/d intravenously for 3 days
Number of subjects: 665
Study 1997047 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam and Thiopentone (combination)
Number of subjects: 300
Study 1997047 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone alone
Number of subjects: 300
Study 1997047 — intervention group
Group type: COMPARATOR
Intervention: Midazolam alone
Number of subjects: 300
Study 6647201 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 17
Study 6647201 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 17
Study 6647201 — intervention group
Group type: COMPARATOR
Intervention: Discontinuation of lipophilic beta-blockers
Number of subjects: 17
Study 31254337 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher ratings on technical skills
Number of subjects: 600
Study 31254337 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher ratings on technical skills for specialists
Number of subjects: 600
Study 29898842 — intervention group
Group type: EXPERIMENTAL
Intervention: ARNI prescription post-guideline publication
Number of subjects: 7200
Study 29898842 — intervention group
Group type: COMPARATOR
Intervention: ARNI prescription pre-guideline publication
Number of subjects: 7200
Study 29898842 — intervention group
Group type: EXPERIMENTAL
Intervention: ARNI use after guideline publication
Number of subjects: 7200
Study 26903712 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week combined endurance and resistance exercise program
Number of subjects: 0
Study 25062420 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle + Drug
Number of subjects: 1112
Study 25062420 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug
Number of subjects: 1112
Study 25062420 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle
Number of subjects: 1112
Study 25062420 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 1112
Study 25062420 — intervention group
Group type: EXPERIMENTAL
Intervention: All intervention groups
Number of subjects: 1112
Study 22693148 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined resistance and aerobic exercise
Number of subjects: 26
Study 22693148 — intervention group
Group type: COMPARATOR
Intervention: Resistance training alone
Number of subjects: 26
Study 19961574 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium ibuprofen (2x256 mg tablets)
Number of subjects: 22
Study 19961574 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen/poloxamer (2x200 mg tablets + 60 mg poloxamer 407)
Number of subjects: 22
Study 19961574 — intervention group
Group type: COMPARATOR
Intervention: Standard ibuprofen (2x200 mg tablets)
Number of subjects: 22
Study 17574819 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy-based low-calorie diet
Number of subjects: 30
Study 17574819 — intervention group
Group type: COMPARATOR
Intervention: Traditional low-calorie diet
Number of subjects: 30
Study 15465544 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-piece Acrysof IOL
Number of subjects: 52
Study 15465544 — intervention group
Group type: COMPARATOR
Intervention: 3-piece Acrysof IOL
Number of subjects: 52
Study 11162323 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive expert system intervention
Number of subjects: 4653
Study 11162323 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert system intervention plus counselor calls
Number of subjects: 4653
Study 11162323 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert system intervention plus stimulus control computer
Number of subjects: 4653
Study 11162323 — intervention group
Group type: COMPARATOR
Intervention: Assessment only condition
Number of subjects: 4653
Study 9549651 — intervention group
Group type: EXPERIMENTAL
Intervention: Felbamate (3,000 or 3,600 mg/day)
Number of subjects: 2
Study 9549651 — intervention group
Group type: COMPARATOR
Intervention: Felbamate (3,000 or 3,600 mg/day) with erythromycin (333 mg three times daily for 10 days)
Number of subjects: 2
Study 9549651 — intervention group
Group type: COMPARATOR
Intervention: Felbamate with erythromycin
Number of subjects: 2
Study 8036686 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC) treatment
Number of subjects: 193
Study 2564058 — intervention group
Group type: EXPERIMENTAL
Intervention: Edwards‐Duromedics valve
Number of subjects: 434
Study 2564058 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic‐Hall valve
Number of subjects: 434
Study 2564058 — intervention group
Group type: COMPARATOR
Intervention: Björk‐Shiley valve
Number of subjects: 434
Study 30362964 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomic signature (six-feature radiomic signature)
Number of subjects: 233
Study 30362964 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for individualized survival prediction
Number of subjects: 233
Study 27646142 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented tapered femoral stem
Number of subjects: 140
Study 27646142 — intervention group
Group type: COMPARATOR
Intervention: Uncemented tapered hydroxyapatite‐coated femoral stem
Number of subjects: 140
Study 25672274 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula enriched with eicosapentaenoic acid (EPA), gamma-linolenic acid (GLA) and antioxidants
Number of subjects: 120
Study 25672274 — intervention group
Group type: COMPARATOR
Intervention: Control formula
Number of subjects: 120
Study 23652752 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate 0.4% ointment
Number of subjects: 41
Study 23652752 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine chlorohydrate 2.5% gel
Number of subjects: 41
Study 20660806 — intervention group
Group type: EXPERIMENTAL
Intervention: REG1 (RB006)
Number of subjects: 24
Study 20660806 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 24
Study 20660806 — intervention group
Group type: EXPERIMENTAL
Intervention: RB006 with partial reversal (RB007)
Number of subjects: 24
Study 20660806 — intervention group
Group type: EXPERIMENTAL
Intervention: RB007 (complete reversal)
Number of subjects: 24
Study 18086170 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 54
Study 18086170 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 100 mg
Number of subjects: 54
Study 18086170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 17168431 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glutamine
Number of subjects: 60
Study 17168431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 14609909 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.06% ISV-205
Number of subjects: 136
Study 14609909 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% ISV-205
Number of subjects: 136
Study 14609909 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 136
Study 11096144 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein diet
Number of subjects: 1494
Study 11096144 — intervention group
Group type: COMPARATOR
Intervention: Higher protein diet
Number of subjects: 1494
Study 8889855 — intervention group
Group type: EXPERIMENTAL
Intervention: High calcium intake (greater than 1000 mg/day) with physical activity
Number of subjects: 17
Study 8889855 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean calcium intake less than 1000 mg/day with physical activity
Number of subjects: 17
Study 8889855 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium intake modifying effect on BMD among exercise groups
Number of subjects: 17
Study 1294894 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (15 mg)
Number of subjects: 36
Study 1294894 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone (15 mg)
Number of subjects: 36
Study 1294894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 3882308 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 8 mg/kg
Number of subjects: 40
Study 3882308 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 10 mg/kg
Number of subjects: 40
Study 3882308 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 12 mg/kg
Number of subjects: 40
Study 3882308 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 14 mg/kg
Number of subjects: 40
Study 3882308 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (all doses except 0 mg/kg)
Number of subjects: 40
Study 3882308 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 40
Study 30740297 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (DB group; 120 mg per 4 weeks plus an additional 120 mg on days 8 and 15; n=125)
Number of subjects: 250
Study 30740297 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic acid (ZA group; 4 mg per 4 weeks; n=125)
Number of subjects: 250
Study 30740297 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (DB group)
Number of subjects: 250
Study 29713250 — intervention group
Group type: EXPERIMENTAL
Intervention: β-alanine (BA) supplementation
Number of subjects: 30
Study 26869181 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced model of early infant primary care with targeted support and care coordination for Aboriginal families, starting during the antenatal period or after birth.
Number of subjects: 0
Study 26869181 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced model of early infant primary care
Number of subjects: 0
Study 25070824 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive positive pressure ventilation (NPPV) applied during a 2-hour spontaneous breathing trial (SBT-2)
Number of subjects: 102
Study 25070824 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive positive pressure ventilation (NPPV) applied during pulmonary infection control (PIC) window
Number of subjects: 102
Study 23000471 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical activation with 10 s waiting interval (ECB)
Number of subjects: 48
Study 23000471 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical activation with 30 s waiting interval (CDB)
Number of subjects: 48
Study 23000471 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical activation with 0 s waiting interval (UNB)
Number of subjects: 48
Study 23000471 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemical activation with 0 s waiting interval (BTB)
Number of subjects: 48
Study 23000471 — intervention group
Group type: COMPARATOR
Intervention: Light activation of all adhesives
Number of subjects: 48
Study 20236990 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET) delivered by trained nurses in three individual appointments
Number of subjects: 117
Study 20236990 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control group
Number of subjects: 117
Study 19388288 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic-impregnated ventricular catheter (Group A)
Number of subjects: 110
Study 19388288 — intervention group
Group type: COMPARATOR
Intervention: Plain ventricular catheters with prophylactic dual antibiotics (Group B)
Number of subjects: 110
Study 16255448 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (instruction burden) - instructions to complete the supplementary questionnaire if certain questions in the primary questionnaire were answered.
Number of subjects: 4494